MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.25
-0.31
-5.58%
After Hours: 5.36 +0.11 +2.10% 18:56 05/10 EDT
OPEN
5.50
PREV CLOSE
5.56
HIGH
5.55
LOW
5.14
VOLUME
1.41M
TURNOVER
--
52 WEEK HIGH
10.56
52 WEEK LOW
1.490
MARKET CAP
259.16M
P/E (TTM)
-5.5003
1D
5D
1M
3M
1Y
5Y
Brighton Jones Llc Buys Oncternal Therapeutics Inc, Snowflake Inc, AMC Entertainment Holdings ...
GuruFocus News · 3d ago
DJ Oncternal Therapeutics, Inc. CEO Jim Breitmeyer on Q1 2021 Results -- Earnings Call Transcript >ONCT
Dow Jones · 3d ago
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 4d ago
Oncternal Therapeutics EPS misses by $0.02, misses on revenue
Oncternal Therapeutics (ONCT): Q1 GAAP EPS of -$0.12 misses by $0.02.Revenue of $0.75M (+29.3% Y/Y) misses by $0.36M.As of March 31, 2021, we had $111.2 million in cash and cash
Seekingalpha · 4d ago
BRIEF-Oncternal Provides Business Update And Announces First Quarter 2021 Financial Results
reuters.com · 4d ago
Earnings Scheduled For May 6, 2021
  Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
Benzinga · 4d ago
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non...
GlobeNewswire · 05/03 21:01
Oncternal Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update
GlobeNewswire · 04/29 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCT. Analyze the recent business situations of Oncternal Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCT stock price target is 15.50 with a high estimate of 21.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 8.45M
% Owned: 17.13%
Shares Outstanding: 49.36M
TypeInstitutionsShares
Increased
9
2.18M
New
34
5.18M
Decreased
3
426.15K
Sold Out
6
2.73M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Independent Director
David Hale
President/Chief Executive Officer/Director
James Breitmeyer
Chief Financial Officer/Treasurer/Secretary
Richard Vincent
Chief Scientific Officer
Gunnar Kaufmann
General Counsel
Chase Leavitt
Other
Igor Bilinsky
Director
Man Cho
Director
Rosemary Mazanet
Director
Robert Wills
Director
Nakanishi Xin
Independent Director
Michael Carter
Independent Director
Daniel Kisner
Independent Director
William LaRue
Independent Director
Charles Theuer
No Data
About ONCT
Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Webull offers kinds of Oncternal Therapeutics Inc stock information, including NASDAQ:ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.